Opinion|Videos|July 12, 2024 (Updated: July 12, 2024)
ADCs Targeting GI Cancers
Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please review the data for T-DM1 for:
- HER2+ advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocaricoma: GATSBY; Shah-Gastric Cancer_2019: Biomarker analysis of GATSBY
- T-DM1 + Pertuzumab for HER2-amplified colorectal cancer: HERACLES-B trial
- Please review the data for T-DXd for:
- HER2+ gastric or GEJ: DESTINY-Gastric01; Shitara_Nature Med_2024: Biomarker Analysis of DESTINY-Gastric01 and DESTINY-Gastric02
- Unresectable or metastatic HER2+ CRC: DESTINY-CRC01 1. DESTINY-CRC02 – Raghav_ASCO 2023
- HER2+ and HER2-low GC: DESTINY-Gastric03 Janjigian ASCO 2024
- Retrospective Cohort Study EN-DEAVOR: Nakanishi ASCO 2024
- What is the potential for HER2-targeting ADCs in other GI cancers?
- Biliary Tract Cancers, Pancreatic
- PanTumor02: Meric-Bernstam_J Clin Oncol_2024; a. BTC and PC Cohort Outcomes: Oh ASCO 2024 #4090
- HERB trial (BTC): Ohba_ASCO2022
- Biliary Tract Cancers, Pancreatic
- Where do HER2-directed ADCs fit into the treatment armamentarium for GI cancers?
- Is there an unmet need ADCs could help fill?
Advertisement
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
The FDA approved atezolizumab plus chemotherapy for the adjuvant treatment of stage III mismatch repair–deficient colon cancer.
The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.
MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
4
MAVERICK, B7-H3–Directed ADCs, and ADAURA Data Headline Key Lung Cancer Findings From WCLC 2026
5